Oncology Therapy Equipment Supplied In Asia & Middle East

Open system for universal IV sets Applicable for blood transfusion, nutrition support and oncology ...

It is the only bevacizumab with metastatic colorectal cancer Phase III clinical data in China and proposed to be combined with HANSIZHUANG (PD-1) for immuno-oncology combination therapies to treat various ...

(serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors in March 2022, providing an alternative treatment option for patients with MSI-H solid tumors. Henlius actively promotes HANSIZHUANG in conjunction with in-house products of the company and ...

TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively targeted ...

Supported by rigorous clinical evidence, Vereos is the world’s first and only fully digital, clinically proven, PET/CT solution . With proprietary Digital Photon Counting technology for outstanding advances all along the imaging chain, Vereos exemplifies an established total solution to reveal more, earlier, to help you improve patient care and manage ...

A plug-and-play system for microfluidic single-cell hydrogel encapsulation; This ready-to-use Microfluidic Hydrogel Kit, combining the novel CYTRIX hydrogel with Sphere Fluidics’ Pico-Gen™ double aqueous biochip and Pico-Surf™ surfactant, ...